{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:52:11Z","timestamp":1793836331605,"version":"4.6.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.critrevonc.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T07:17:47Z","timestamp":1370416667000},"page":"284-292","source":"Crossref","is-referenced-by-count":30,"title":["P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency"],"prefix":"10.1016","volume":"88","author":[{"given":"Iuliana","family":"Shapira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Budman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9793","key":"10.1016\/j.critrevonc.2013.05.003_bib0005","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.05.003_bib0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CCO.0b013e32834bd4c9","article-title":"HER2-overexpressing breast cancer: time for the cure with less chemotherapy?","volume":"23","author":"Loi","year":"2011","journal-title":"Current Opinion in Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.05.003_bib0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumours: a critical review","volume":"52","author":"Reis-Filho","year":"2008","journal-title":"Histopathology"},{"issue":"9805","key":"10.1016\/j.critrevonc.2013.05.003_bib0020","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","article-title":"Gene expression profiling in breast cancer: classification, prognostication, and prediction","volume":"378","author":"Reis-Filho","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2012.08.003","article-title":"Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?","author":"Fumagalli","year":"2012","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.05.003_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.05.003_bib0035","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2011.03.006","article-title":"Genomic analysis: toward a new approach in breast cancer management","volume":"81","author":"Cavallaro","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7418","key":"10.1016\/j.critrevonc.2013.05.003_bib0045","first-page":"61","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2011","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.critrevonc.2013.05.003_bib0050","first-page":"73","article-title":"Molecular profiling of triple negative breast cancer","volume":"32","author":"Ma","year":"2010","journal-title":"Breast Disease"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.05.003_bib0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4161\/epi.6.5.15667","article-title":"CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer","volume":"6","author":"Stefansson","year":"2011","journal-title":"Epigenetics"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.05.003_bib0060","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/sj.onc.1202509","article-title":"Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics","volume":"18","author":"Catteau","year":"1999","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.05.003_bib0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.05.003_bib0070","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-08-1560","article-title":"High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors","volume":"69","author":"Manie","year":"2009","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.05.003_bib0075","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-08-3426","article-title":"High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer","volume":"69","author":"Holstege","year":"2009","journal-title":"Cancer Research"},{"issue":"6797","key":"10.1016\/j.critrevonc.2013.05.003_bib0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.05.003_bib0085","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/onc.2010.518","article-title":"Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes","volume":"30","author":"Tabaries","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0090","doi-asserted-by":"crossref","first-page":"p309","DOI":"10.1186\/1471-2407-8-309","article-title":"Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers","volume":"8","author":"Toyama","year":"2008","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2013.05.003_bib0095","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/modpathol.3800961","article-title":"Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2\/neu (basal-like breast carcinomas)","volume":"20","author":"Lerma","year":"2007","journal-title":"Modern Pathology"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.05.003_bib0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-008-0206-z","article-title":"Invasive ductal carcinoma of the breast with the \u201ctriple-negative\u201d phenotype: prognostic implications of EGFR immunoreactivity","volume":"116","author":"Viale","year":"2009","journal-title":"Breast Cancer Research and Treatment"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.05.003_bib0105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/modpathol.3800438","article-title":"EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations","volume":"18","author":"Bhargava","year":"2005","journal-title":"Modern Pathology"},{"issue":"19","key":"10.1016\/j.critrevonc.2013.05.003_bib0110","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.05.003_bib0115","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/MCB.26.8.2877-2886.2006","article-title":"Multiple functions of the integrin alpha6beta4 in epidermal homeostasis and tumorigenesis","volume":"26","author":"Wilhelmsen","year":"2006","journal-title":"Molecular and Cellular Biology"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.05.003_bib0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.05.003_bib0125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0014-4827(03)00002-8","article-title":"Trafficking of the ErbB receptors and its influence on signaling","volume":"284","author":"Wiley","year":"2003","journal-title":"Experimental Cell Research"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.05.003_bib0130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1349-7006.2007.00676.x","article-title":"Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands","volume":"99","author":"Higashiyama","year":"2008","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.05.003_bib0135","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1242\/dev.126.12.2739","article-title":"Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development","volume":"126","author":"Luetteke","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1749-6632.2003.tb03207.x","article-title":"TACE\/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase","volume":"995","author":"Lee","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0145","doi-asserted-by":"crossref","first-page":"e34515","DOI":"10.1371\/journal.pone.0034515","article-title":"Network analysis of epidermal growth factor signaling using integrated genomic, proteomic and phosphorylation data","volume":"7","author":"Waters","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0150","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-007-9748-8","article-title":"Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells","volume":"110","author":"Gilmore","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.05.003_bib0155","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jcb.22505","article-title":"Compartmentalization of EGFR in cellular membranes: role of membrane rafts","volume":"109","author":"Balbis","year":"2010","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.05.003_bib0160","doi-asserted-by":"crossref","first-page":"e30255","DOI":"10.1371\/journal.pone.0030255","article-title":"Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad","volume":"7","author":"Nickerson","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0165","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer","author":"Masuda","year":"2012","journal-title":"Breast Cancer Research Treatment"},{"issue":"1\u20134","key":"10.1016\/j.critrevonc.2013.05.003_bib0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0079-6336(11)80076-8","article-title":"Visualization and quantitative analysis of epidermal growth factor (EGF) receptors at electron microscopical level","volume":"26","author":"van Belzen","year":"1992","journal-title":"Progress in Histochemistry and Cytochemistry"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.05.003_bib0175","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1074\/jbc.271.9.5251","article-title":"All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired","volume":"271","author":"Baulida","year":"1996","journal-title":"Journal of Biological Chemistry"},{"issue":"17","key":"10.1016\/j.critrevonc.2013.05.003_bib0180","first-page":"3093","article-title":"Endocytosis and intracellular trafficking of ErbBs","volume":"314","author":"Sorkin","year":"2008","journal-title":"Experimental Cell Research"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.05.003_bib0185","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/carcin\/bgs128","article-title":"The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner","volume":"33","author":"Sak","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0190","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2119\/molmed.2011.00217","article-title":"Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling","volume":"18","author":"Coniglio","year":"2012","journal-title":"Molecular Medicine"},{"issue":"24","key":"10.1016\/j.critrevonc.2013.05.003_bib0195","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1158\/0008-5472.CAN-09-1868","article-title":"Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor","volume":"69","author":"Patsialou","year":"2009","journal-title":"Cancer Research"},{"issue":"33","key":"10.1016\/j.critrevonc.2013.05.003_bib0200","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1074\/jbc.271.33.20047","article-title":"The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4","volume":"271","author":"Riese","year":"1996","journal-title":"Journal of Biological Chemistry"},{"issue":"49","key":"10.1016\/j.critrevonc.2013.05.003_bib0205","doi-asserted-by":"crossref","first-page":"37728","DOI":"10.1074\/jbc.M606532200","article-title":"Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells","volume":"281","author":"Willmarth","year":"2006","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.05.003_bib0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0b013e3181d24fc1","article-title":"Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?","volume":"16","author":"Burness","year":"2010","journal-title":"Cancer Journal"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.05.003_bib0215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00666180","article-title":"The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients","volume":"29","author":"Fox","year":"1994","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.05.003_bib0220","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1075-122X.2006.00276.x","article-title":"The challenging estrogen receptor-negative\/progesterone receptor-negative\/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?","volume":"12","author":"Siziopikou","year":"2006","journal-title":"Breast J"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.05.003_bib0225","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrm2755","article-title":"Pathways and mechanisms of endocytic recycling","volume":"10","author":"Grant","year":"2009","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.05.003_bib0230","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1074\/jbc.M808171200","article-title":"Tyrosine kinase activity of epidermal growth factor receptor is regulated by GM3 binding through carbohydrate to carbohydrate interactions","volume":"284","author":"Kawashima","year":"2009","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.05.003_bib0235","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1074\/jbc.M510893200","article-title":"Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling","volume":"281","author":"Wang","year":"2006","journal-title":"Journal of Biological Chemistry"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.05.003_bib0240","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0962-8924(01)02107-9","article-title":"Endocytosis without clathrin coats","volume":"11","author":"Nichols","year":"2001","journal-title":"Trends in Cell Biology"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.05.003_bib0245","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1034\/j.1600-0854.2002.30701.x","article-title":"Clathrin-dependent or not: is it still the question?","volume":"3","author":"Johannes","year":"2002","journal-title":"Traffic"},{"issue":"30","key":"10.1016\/j.critrevonc.2013.05.003_bib0250","doi-asserted-by":"crossref","first-page":"27433","DOI":"10.1074\/jbc.M201595200","article-title":"Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor","volume":"277","author":"Sorkina","year":"2002","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.05.003_bib0255","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrm2799","article-title":"Integrins: masters and slaves of endocytic transport","volume":"10","author":"Caswell","year":"2009","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0260","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1476-4598-9-312","article-title":"Integrin-mediated function of Rab GTPases in cancer progression","volume":"9","author":"Subramani","year":"2010","journal-title":"Molecular Cancer"},{"issue":"7280","key":"10.1016\/j.critrevonc.2013.05.003_bib0265","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature08910","article-title":"The endocytic matrix","volume":"463","author":"Scita","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.05.003_bib0270","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","article-title":"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer","volume":"12","author":"Olivier","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.05.003_bib0275","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/humu.10081","article-title":"The IARC TP53 database: new online mutation analysis and recommendations to users","volume":"19","author":"Olivier","year":"2002","journal-title":"Human Mutation"},{"issue":"15","key":"10.1016\/j.critrevonc.2013.05.003_bib0280","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/sj.onc.1210295","article-title":"Reactivation of mutant p53: molecular mechanisms and therapeutic potential","volume":"26","author":"Selivanova","year":"2007","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.critrevonc.2013.05.003_bib0285","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nature Reviews Cancer"},{"issue":"7291","key":"10.1016\/j.critrevonc.2013.05.003_bib0290","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nature08989","article-title":"Genome remodelling in a basal-like breast cancer metastasis and xenograft","volume":"464","author":"Ding","year":"2010","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.critrevonc.2013.05.003_bib0295","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1093\/hmg\/ddn190","article-title":"Somatic microindels in human cancer: the insertions are highly error-prone and derive from nearby but not adjacent sense and antisense templates","volume":"17","author":"Scaringe","year":"2008","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0300","article-title":"High frequency of complex TP53 mutations in CNS metastases from breast cancer","author":"Lo Nigro","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0305","first-page":"403","article-title":"BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells","volume":"7","author":"Molyneux","year":"2010","journal-title":"Stem Cell Stem"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.05.003_bib0310","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2009.11.026","article-title":"Mutant p53 drives invasion by promoting integrin recycling","volume":"139","author":"Muller","year":"2009","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2013.05.003_bib0315","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1073\/pnas.97.8.4174","article-title":"High metastatic potential in mice inheriting a targeted p53 missense mutation","volume":"97","author":"Liu","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.05.003_bib0320","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome","volume":"119","author":"Lang","year":"2004","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.05.003_bib0325","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.05.003_bib0330","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1074\/jbc.M504175200","article-title":"rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome","volume":"281","author":"Ceresa","year":"2006","journal-title":"Journal of Biological Chemistry"},{"issue":"15","key":"10.1016\/j.critrevonc.2013.05.003_bib0335","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/sj.onc.1210311","article-title":"Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?","volume":"26","author":"Li","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.critrevonc.2013.05.003_bib0340","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.bbrc.2007.04.052","article-title":"Involvement of Rabring7 in EGF receptor degradation as an E3 ligase","volume":"357","author":"Sakane","year":"2007","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"12","key":"10.1016\/j.critrevonc.2013.05.003_bib0345","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1091\/mbc.E07-02-0098","article-title":"Late endosomal traffic of the epidermal growth factor receptor ensures spatial and temporal fidelity of mitogen-activated protein kinase signaling","volume":"18","author":"Taub","year":"2007","journal-title":"Molecular Biology of the Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2013.05.003_bib0350","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cell.2009.01.039","article-title":"A Mutant-p53\/Smad complex opposes p63 to empower TGFbeta-induced metastasis","volume":"137","author":"Adorno","year":"2009","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2013.05.003_bib0355","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/1541-7786.371.2.7","article-title":"p63 and p73: roles in development and tumor formation","volume":"2","author":"Moll","year":"2004","journal-title":"Molecular Cancer Research"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0360","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cell.2007.02.045","article-title":"p63 Is essential for the proliferative potential of stem cells in stratified epithelia","volume":"129","author":"Senoo","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0365","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4161\/cc.6.3.3797","article-title":"TAp63 and DeltaNp63 in cancer and epidermal development","volume":"6","author":"Candi","year":"2007","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.critrevonc.2013.05.003_bib0370","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-10-2717","article-title":"The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer","volume":"71","author":"Buckley","year":"2011","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.05.003_bib0375","doi-asserted-by":"crossref","first-page":"a001057","DOI":"10.1101\/cshperspect.a001057","article-title":"p53 regulation of the IGF-1\/AKT\/mTOR pathways and the endosomal compartment","volume":"2","author":"Feng","year":"2010","journal-title":"Cold Spring Harbor Perspectives Biology"},{"issue":"Suppl. (1)","key":"10.1016\/j.critrevonc.2013.05.003_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S1-01","article-title":"Triple-negative breast cancer: an unmet medical need","volume":"16","author":"Hudis","year":"2011","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2013.05.003_bib0385","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tcb.2008.03.004","article-title":"Endocytic transport of integrins during cell migration and invasion","volume":"18","author":"Caswell","year":"2008","journal-title":"Trends in Cell Biology"},{"issue":"15","key":"10.1016\/j.critrevonc.2013.05.003_bib0390","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1158\/0008-5472.CAN-09-0049","article-title":"Cetuximab\/C225-induced intracellular trafficking of epidermal growth factor receptor","volume":"69","author":"Liao","year":"2009","journal-title":"Cancer Research"},{"issue":"14","key":"10.1016\/j.critrevonc.2013.05.003_bib0395","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1091\/mbc.E09-03-0256","article-title":"Endocytic accessory proteins are functionally distinguished by their differential effects on the maturation of clathrin-coated pits","volume":"20","author":"Mettlen","year":"2009","journal-title":"Molecular Biology of the Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0400","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2011.06.025","article-title":"Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition","volume":"146","author":"von Kleist","year":"2011","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.05.003_bib0405","doi-asserted-by":"crossref","first-page":"e45799","DOI":"10.1371\/journal.pone.0045799","article-title":"Pitstop 2 is a potent inhibitor of clathrin-independent endocytosis","volume":"7","author":"Dutta","year":"2012","journal-title":"PLoS ONE"},{"issue":"16","key":"10.1016\/j.critrevonc.2013.05.003_bib0410","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1158\/0008-5472.CAN-08-0137","article-title":"Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells","volume":"68","author":"Guida","year":"2008","journal-title":"Cancer Research"},{"issue":"1\u20132","key":"10.1016\/j.critrevonc.2013.05.003_bib0415","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Freed-Pastor","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2013.05.003_bib0420","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CBC.2006.n.040","article-title":"A phase I study of cetuximab\/paclitaxel in patients with advanced-stage breast cancer","volume":"7","author":"Modi","year":"2006","journal-title":"Clinical Breast Cancer"},{"issue":"24 (Suppl)","key":"10.1016\/j.critrevonc.2013.05.003_bib0425","article-title":"Cetuximab+Cisplatin in estrogen receptor-negative, progesteron receptor negative, Her2-negative (triple negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial","volume":"70","author":"Baselga","year":"2010","journal-title":"Cancer Research"},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2013.05.003_bib0430","article-title":"Efficacy of cetuximab plus platinum agent in advanced, triple negative breast carcinoma: Results of a retrospective analysis","volume":"29","author":"Rivera","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppi","key":"10.1016\/j.critrevonc.2013.05.003_bib0435","article-title":"Panitumumab in combination with FEC100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple negative breast cancer (TNBC): preliminary results of a multicenter neoadjuvant pilot phase II study","volume":"29","author":"Nabholtz","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"supplement32","key":"10.1016\/j.critrevonc.2013.05.003_bib0440","article-title":"Preliminary results of a randomized phase II study of weekly irinotecan and carboplatin with or without cetuximab in patients with metastatic breast cancer","volume":"106","author":"O'Shaughnessy","year":"2007","journal-title":"Breast Cancer Research and Treatment"},{"issue":"21","key":"10.1016\/j.critrevonc.2013.05.003_bib0445","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer","volume":"30","author":"Carey","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2013.05.003_bib0450","article-title":"BIBW 2992, a novel irreversible EGFR\/Her1 and Her2 tyrosine kinase inhibitor, for the treatment of patients with Her2 negative metastatic breast cancer after failure of no more than two prior chemotherapies","volume":"28","author":"Schuller","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.critrevonc.2013.05.003_bib0455","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-011-1352-2","article-title":"Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial","volume":"126","author":"Bernsdorf","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0460","unstructured":"http:\/\/clinicaltrials.gov\/show\/NCT01097642, Accessed March 30, 2013"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0465","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00491816, Accessed on March 30 2013"},{"key":"10.1016\/j.critrevonc.2013.05.003_bib0470","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00600249, Accessed March 30, 2013"},{"issue":"23","key":"10.1016\/j.critrevonc.2013.05.003_bib0475","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1242\/dev.084467","article-title":"Endocytic receptor-mediated control of morphogen signaling","volume":"139","author":"Willnow","year":"2012","journal-title":"Development"},{"issue":"9","key":"10.1016\/j.critrevonc.2013.05.003_bib0480","doi-asserted-by":"crossref","first-page":"e45280","DOI":"10.1371\/journal.pone.0045280","article-title":"Monitoring the cytoskeletal EGF response in live gastric carcinoma cells","volume":"7","author":"Felkl","year":"2012","journal-title":"PLoS ONE"},{"issue":"7399","key":"10.1016\/j.critrevonc.2013.05.003_bib0485","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nature11133","article-title":"Rab5 is necessary for the biogenesis of the endolysosomal system in vivo","volume":"485","author":"Zeigerer","year":"2012","journal-title":"Nature"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T21:09:12Z","timestamp":1715461752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1040842813000978"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.05.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}